Please assess the completion status of the following clinical trial:

Trial Title: Statin Combination Therapy in Patients Receiving Sorafenib for Advanced Hepatocellular Carcinoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients more than 40 years old~2. HCCs diagnosed by AASLD image criteria or pathology~3. HCCs in BCLC advanced stage, with portal vein thrombosis (VP3 or VP4) or extrahepatic metastasis~4. Not suitable or failed to locoreginal treatments for HCC~5. Child-Pugh score = or \< 6~6. ECOG performance status (PST) 0-2~7. Serum bilirubin \< 2 mg/dL and prothrombin time (PT) prolongation \< 3 seconds~8. Will receive sorafenib therapy~9. Life expectancy \> 3 months~10. Will follow the pregnancy prevention protocol~Exclusion Criteria:~1. HCC is considered for curative therapy~2. HCC with brain metastasis~3. History of systemic therapy for HCC~4. Indications for statin use, such as hyperlipidemia in cardiovascular diseases~5. Any local treatment for HCC within 4 weeks~6. Any active gastrointestinal bleeding within 4 weeks~7. Liver transplant history or concomitant immunosuppressive therapy~8. Concurrent any other malignancy~9. Allergy to sorafenib or statins~10. Pregnancy or lactation~11. Serum AST or ALT \> 5x upper limit of normal~12. Known HIV infection~13. eGFR \< 30 ml/min~14. Abnormal medical conditions that are unsuitable for study, such as uncontrolled hypertension, coronary arterial disease, or arrhythmia

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Statin treated group (Type: EXPERIMENTAL): None
- Control group (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).